


Fruquintinib FRESCO -2

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Reviewed, but not qualified for an ESMO-MCBS credit

Serious and disabling adverse effects




Other adjustments



Fruquintinib FRESCO -2

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers  
Therapeutic Indication: Fruquintinib for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, if RAS wild-type and medically appropriate, an anti-EGFR therapy, and at least one of trifluridine/tipiracil or regorafenib.  
Experimental Arm: Fruquintinib + Best supportive care  
Control Arm: Placebo + best supportive care



